Nordson to acquire Atrion for $460/share in cash, ~$800M enterprise value

NORDSON CORP

Deal price $460/share cash; enterprise value ~$800M; 15x 2024 estimated EBITDA including expected synergies.
Atrion 2023 revenue ~$169M; key businesses: Halkey Roberts, Atrion Medical, Quest Medical in infusion and cardiovascular.
Expected close before Nordson fiscal year-end Oct 2024; funded by cash on hand and new debt.
Three FDA-registered U.S. manufacturing facilities expand Nordson MEDICAL's addressable market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.